The Race for Avandia's Share: May the Safest Product Win
This article was originally published in RPM Report
Executive Summary
The safety problems with GlaxoSmithKline's Avandia have left a large chunk of the diabetes market open to competing products, and the outcome of an FDA advisory committee meeting could leave even more up for grabs. Who will be the big winner in the race for market share?